Stanford Scientists Regrow Cartilage, Halt Arthritis Progression

A study led by Stanford Medicine researchers has‍ found that an injection blocking a protein linked to aging can reverse the natural loss of knee cartilage in older mice. The same treatment also stopped⁤ arthritis from‌ developing after knee injuries ‌that resemble ACL tears,which are‌ common among athletes and recreational exercisers. Researchers note that an oral version of the‍ treatment is ⁣already being tested in clinical trials aimed at treating age-related muscle weakness.

Human cartilage samples taken from knee replacement surgeries also responded positively. Thes samples included both the supportive extracellular matrix of the joint and cartilage-producing chondrocyte cells. When treated, the tissue began​ forming new, functional cartilage.

Together, the findings suggest that cartilage lost due to aging or arthritis may one day be restored using ⁤either a pill or a⁢ targeted injection. If triumphant in people, ⁢such treatments could reduce or even eliminate the need for knee and hip replacement surgery.

A Direct Attack on ⁤osteoarthritis

Osteoarthritis is a degenerative joint disease‌ that affects ‌about one in five adults in the United States and generates an estimated ⁢$65 ⁣billion each year in direct health care ⁤costs. Current ⁢treatments focus on managing pain or replacing damaged joints surgically.There are no approved drugs that can slow or reverse the ⁣underlying cartilage damage.

The new approach targets ‌the root ⁤cause of the disease rather than its symptoms, offering a potential shift in how osteoarthritis is treated.

The Role‌ of a Master Aging Enzyme

The protein at the center of the study is called 15-PGDH. Researchers refer to it as a gerozyme because its levels increase as the body⁢ ages. gerozymes were identified by the ⁢same ‍research team​ in 2023 and are known to drive the gradual loss ‌of tissue ‌function.

In mice, higher levels of 15-PGDH are linked to declining muscle strength with age. Blocking the enzyme using a ⁣small molecule boosted muscle mass and endurance ⁣in older animals. In contrast, forcing ⁢young mice​ to produce more 15-PGDH​ caused their muscles to⁤ shrink and weaken. The ⁢protein has ⁢also been connected‍ to regeneration​ in bone, nerve, and blood cells.

In most of these tissues, repair happens through the activation and⁤ specialization of stem cells.​ Cartilage appears to be different. In this case, chondrocytes change how their genes behave, shifting into a more youthful state without relying on stem cells.

A New Path to Tissue Regeneration

“This⁢ is ⁤a​ new way of regenerating adult tissue,and it has notable clinical promise for treating⁣ arthritis due to aging or ⁤injury,” said Helen Blau,PhD,professor of microbiology and immunology.”We were looking for stem cells, but they are clearly not involved. It’s very exciting.”

Blau, who leads the‍ Baxter Laboratory for Stem Cell ​Biology and ‌holds the Donald E. and Delia⁢ B. Baxter Foundation Professorship, and Nidhi ​Bhutani, PhD, associate professor of orthopaedic surgery, are the study’s senior‍ authors. The research​ was published in Science. ‌Mamta Singla, PhD, instructor of orthopaedic surgery,⁤ and former postdoctoral scholar Yu Xin (Will) Wang, PhD, served as⁢ led authors. wang is now an assistant professor ​at the Sanford Burnham Institute in San Diego.

Dramatic Regeneration of Joint Cartilage

“Millions of people suffer from joint pain​ and swelling ​as they age,” Bhutani said. “It is a huge unmet medical need. Until now, there has been no drug that directly treats ​the cause of cartilage loss. but this⁢ gerozyme inhibitor causes a dramatic regeneration ⁣of cartilage beyond that reported in response to any ⁤other​ drug or intervention.”

The human body contains three main types of‌ cartilage. Elastic cartilage is soft and flexible and forms structures such as⁤ the outer ear. fibrocartilage ‌is dense‍ and tough, helping absorb shock in places like the spaces between ​spinal vertebrae.Hyaline cartilage is smooth and glossy, allowing joints such as the hips, knees, shoulders, and ankles to move with low⁤ friction. ​This type, also called articular cartilage, is the form ⁢most commonly damaged in osteoarthritis.

Why cartilage

Research Shows Potential for cartilage​ Regeneration Through 15-PGDH Inhibition

This report details research suggesting a novel approach to cartilage regeneration by inhibiting the enzyme 15-PGDH.The findings, stemming‍ from studies in mice and human cartilage samples, indicate a potential pathway to reverse ‍cartilage degradation and promote tissue repair without relying on stem or progenitor cells.

Key Findings from Animal Studies

Research conducted on mice demonstrated significant shifts in⁣ gene expression within cartilage tissue ​following treatment ⁣with a‍ 15-PGDH ‍inhibitor. Specifically:

* Genes associated with cartilage degradation and those ⁢promoting fibrocartilage formation decreased. Degradation-related ⁢genes dropped from 8% to 3%, while the fibrocartilage group declined from 16% to 8%.
* A population​ of cells shifted towards a profile characteristic of hyaline ‍cartilage ⁣formation and extracellular matrix maintenance, increasing from 22%⁣ to 42%.
* These changes suggest a reversion to a more youthful⁣ cartilage ⁢profile.

Human Cartilage Sample Results

Further investigation ‍using cartilage samples from patients undergoing total knee ⁣replacement for osteoarthritis showed promising results after one week of treatment with ⁢the ​15-PGDH inhibitor:

* A reduction in the number ⁢of 15-PGDH-producing⁢ chondrocytes.
* Decreased expression of‍ genes linked to cartilage ⁣degradation and fibrocartilage formation.
* ‍Early indications of articular cartilage regeneration.

15-PGDH ⁢Inhibition and Tissue Regeneration

Researchers, including Dr. Nidhi Bhutani, believe the ⁣mechanism​ is significant, highlighting the ability of existing cartilage cells to alter their gene expression patterns. This suggests a potential for⁣ broader clinical impact by targeting these cells for regeneration.

Clinical Trial Outlook

Stanford University and Epirium Bio are pursuing clinical trials.

Phase 1 clinical trials evaluating a 15-PGDH inhibitor for muscle weakness ⁤have already demonstrated safety and activity in healthy volunteers. Plans are underway to launch a similar trial focused on cartilage regeneration.​ Dr. Helen Blau expressed ⁤optimism about the potential to regrow existing cartilage ⁢and avoid the need for joint replacement surgery.

Funding and Potential Conflicts of Interest

The research ⁣was supported by grants from the National institutes of Health (R01AR070864, R01AR077530, R01AG069858 and R00NS120278), the Baxter Foundation for ⁢Stem ‍Cell Biology, the Li Ka ‍Shing Foundation, the Stanford Cardiovascular Institute, the Milky Way⁣ Research Foundation, the Canadian Institutes of Health Research, a Stanford Translational Research and applied Medicine Pilot grant, a GlaxoSmithKline Sir James Black Postdoctoral Fellowship, and a Stanford Dean’s postdoctoral ​Fellowship.

It is noted that Blau, Bhutani, and other co-authors hold ⁣patent applications related to 15-PGDH inhibition​ and‍ have financial ties to Myoforte/Epirium Bio. Blau is a co-founder and holds equity in the company.

Verification Status⁣ (as of ​2026/01/21 12:31:36):

As of⁣ the date of this ‌response, there have been ‍no major, publicly available updates regarding the initiation of Phase ⁣2 ‍clinical trials for 15-PGDH inhibitors in cartilage regeneration beyond the stated intention to launch a trial. A search of ⁤clinical trial registries (e.g.,⁢ clinicaltrials.gov) using keywords “15-PGDH,” “cartilage regeneration,” and “osteoarthritis” does not reveal any trials initiated after ​the publication ​of​ this research.The ​information ‌regarding⁢ Phase 1 trials for muscle ⁢weakness remains consistent ⁣with publicly available data. The funding sources ⁣and conflict of interest ⁢disclosures are consistent ​with ‌information available on the stanford University and Epirium ‍Bio websites.